Every Form 4 that Rani Therapeutics Holdings, Inc. (RANI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RANI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RANI filings page.
Rani Therapeutics Holdings, Inc. director Michelle Gilson received a grant of 247,200 Director Stock Options on 2026-08-03, each for one share of Class A Common Stock at an exercise price of 0.8013 per share, expiring on 2036-08-02.
The options vest over three years: 1/3 on the first anniversary of the grant date and 1/36 monthly thereafter, subject to Continuous Service under the company’s 2021 Equity Incentive Plan, or in full upon a Change in Control. Following this award, Gilson holds 247,200 options directly.
Imran Mir A, a director and 10% owner of Rani Therapeutics Holdings, Inc., purchased 36,000 shares of Class A Common Stock on July 21, 2026 at a weighted average price of about $0.69 per share, in multiple transactions between $0.688 and $0.69. After this purchase, he directly holds 2,119,334 Class A shares and has indirect interests in 74,139 Class A and 22,660,053 Class B shares through affiliated entities, for which he disclaims beneficial ownership beyond his pecuniary interest.
Rani Therapeutics Holdings, Inc. Chief Technical Officer Alireza Javadi reported two dispositions of Class A Common Stock related to restricted stock unit settlements. On March 27, 2026, he sold 386 shares at $0.78 per share to cover tax withholding obligations. On June 27, 2026, 309 shares at $0.74 per share were withheld and surrendered to the issuer to satisfy tax withholding obligations. Both transactions were reported late due to inadvertent administrative oversight.
Rani Therapeutics Holdings, Inc. director and Chief Executive Officer Imran Talat purchased 35,000 shares of Class A Common Stock on July 17, 2026 at $0.7198 per share in an open-market transaction, bringing his direct holdings to 469,736 shares. This total includes 12,343 shares held by VH Moll, L.P., for which he disclaims beneficial ownership except to the extent of his pecuniary interest. The Rule 10b5-1 trading-plan checkbox is unchecked.
Rani Therapeutics Holdings, Inc. director and Chief Executive Officer Imran Talat reported a sale of 8,014 Class A shares at $1.41 on 2024-12-27 to cover tax withholding on restricted stock unit settlement. Between 2025-06-27 and 2026-06-27, an additional 52,001 shares were withheld or surrendered to satisfy RSU-related tax withholding obligations. The report states these transactions were filed late due to inadvertent administrative oversight and notes that reported holdings include 12,343 shares held by VH Moll, L.P., for which Talat disclaims beneficial ownership beyond his pecuniary interest.
Rani Therapeutics Holdings, Inc. reports that its Chief Financial Officer, Nicholas Maestas, received a compensation grant of a stock option on July 17, 2026 covering 2,000,000 shares of Class A common stock at an exercise price of $0.6973 per share. The option expires on July 16, 2036. According to the vesting terms, 25% of the shares vest on June 29, 2027, and 1/48th of the shares vest monthly over the following three years, subject to his Continuous Service under the company’s 2026 Inducement Plan. Following this award, Maestas holds options for 2,000,000 shares.
Rani Therapeutics Holdings, Inc. reported that Chief Business Officer Kate McKinley received a grant of stock options covering 805,500 shares of Class A Common Stock. The options have an exercise price of $0.875 per share and expire on June 2, 2036.
According to the grant terms, one forty-eighth of the options vest monthly over four years starting April 1, 2026, as long as she maintains continuous service with the company. Following this award, she holds 805,500 stock options, aligning a portion of her compensation with the company’s future share performance.
Rani Therapeutics Holdings, Inc. reported that Chief Technical Officer Alireza Javadi received a grant of stock options covering 805,500 shares of Class A common stock. The options have an exercise price of $0.875 per share and expire on June 2, 2036.
According to the grant terms, 1/48th of the options vest monthly over four years starting April 1, 2026, as long as he maintains continuous service with the company. This is a compensation-related award, not an open-market purchase or sale.
Rani Therapeutics Holdings, Inc. reported that Chief Executive Officer Imran Talat received a grant of stock options covering 3,800,000 shares of Class A Common Stock. The options have an exercise price of $0.875 per share and expire on June 2, 2036.
According to the award’s terms, 1/48th of the underlying shares vest monthly over four years starting April 1, 2026, conditioned on his continued service with the company. Following this grant, Talat holds stock options on 3,800,000 shares directly, with no open-market buys or sells reported in this filing.
Rani Therapeutics Holdings director Abraham Bassan received a grant of 123,600 stock options for Class A Common Stock. The options were awarded at an exercise price of $0.9515 per share and represent his entire reported derivative holdings after this transaction.
The option grant vests in full on the first anniversary of the grant date, subject to his continued service. Vesting may occur earlier if the company holds its next annual stockholder meeting or if a Change in Control occurs, provided he maintains Continuous Service through that date.
Rani Therapeutics Holdings director Lisa Ann Rometty received a stock option grant covering 123,600 shares of Class A common stock. The option has an exercise price of $0.9515 per share and expires on May 27, 2036.
The option vests in full on the first anniversary of the May 28, 2026 grant date, subject to her Continuous Service under the company’s 2021 Equity Incentive Plan. Vesting may occur earlier if either the company’s next annual stockholder meeting or a Change in Control occurs while she continues in service. Following this grant, she holds 123,600 option shares directly.
Rani Therapeutics Holdings, Inc. director and ten percent owner Imran Mir A received a grant of options to acquire 123,600 shares of Class A Common Stock. The options have an exercise price of 0.9515 per share and expire on May 27, 2036.
These director stock options vest in full on the first anniversary of the grant date, subject to continuous service, or earlier upon the company’s next annual stockholder meeting or a Change in Control, also subject to continuous service. Following this grant, the filing shows 123,600 derivative securities held directly.
Rani Therapeutics Holdings director Jean Luc Butel received a grant of stock options covering 123,600 shares of Class A common stock. The options have an exercise price of $0.9515 per share and expire on May 27, 2036.
The options were awarded as compensation, not purchased in the open market. According to the award terms, the options vest in full on the first anniversary of the May 28, 2026 grant date, provided the director maintains Continuous Service. They may vest earlier if the company holds its next annual stockholder meeting or undergoes a Change in Control while the director remains in service.
Rani Therapeutics director Bailey Vasudev Jaiprakash received a stock option grant covering 123,600 shares of Class A common stock. The option was awarded on May 28, 2026 at an exercise price of $0.9515 per share and is held directly.
The option vests in full on the first anniversary of the grant date, subject to the director’s continuous service under the company’s 2021 Equity Incentive Plan. Vesting can occur earlier if Rani Therapeutics holds its next annual stockholder meeting or if a Change in Control occurs, in each case only if continuous service requirements are met. After this grant, the director holds 123,600 derivative securities related to this option.
Rani Therapeutics Holdings director Dennis A. Ausiello received a grant of stock options covering 123,600 shares of Class A common stock. The options have an exercise price of $0.9515 per share and expire on May 27, 2036. This is a compensation-related award rather than an open-market purchase.
The options vest in full on the first anniversary of the grant date, subject to Dr. Ausiello’s continuous service. Vesting can occur earlier if either the company’s next annual stockholder meeting or a Change in Control happens while he remains in continuous service. Following this grant, he holds options for 123,600 shares directly.
Rani Therapeutics (RANI): Director equity grant reported. A director was granted a stock option covering 100,000 shares of Class A common stock on 10/23/2025 at an exercise price of $2.09 per share. The option expires on 10/22/2035.
The award vests over three years: one-third on October 23, 2026, then one‑thirty‑sixth monthly thereafter, subject to continuous service. Following the grant, 100,000 derivative securities were beneficially owned, held directly.
Rani Therapeutics Holdings, Inc. (RANI) reported a Form 4 showing a director received a stock option grant for 100,000 shares of Class A common stock at an exercise price of $2.09 per share on October 23, 2025.
The option expires on October 22, 2035 and vests over three years: one-third on October 23, 2026, then 1/36 monthly thereafter, subject to continuous service. Following the grant, 100,000 derivative securities were beneficially owned directly.
Rani Therapeutics (RANI) reported insider activity: Director and 10% owner Mir A. Imran purchased 2,083,334 shares of Class A common stock at $0.605 on 10/23/2025 in a PIPE offering. He also acquired warrants to purchase 2,083,334 Class A shares with a $0.48 exercise price, which are exercisable upon stockholder approval and carry a five-year term from the date of such approval.
Following the transactions, he beneficially owns 2,083,334 Class A shares directly. Indirect holdings are reported as 74,139 Class A shares and 22,660,053 Class B shares through affiliated entities, subject to stated pecuniary interest disclaimers.
Rani Therapeutics (RANI) reported insider share sales on a Form 4. The reporting person executed open‑market sales of Class A common stock on two dates. On 10/20/2025, they sold 1,923,000 shares at a weighted average price of $2.4115. On 10/21/2025, they sold 4,000,000 shares at a weighted average price of $2.7685.
Following these transactions, the reporting person beneficially owned 2,379,194 shares, held indirectly through South Lake One LLC. The filing notes that the weighted average prices reflect multiple trades within ranges of $2.25–$2.61 and $2.50–$3.09, and detailed trade breakdowns are available upon request. The ownership is reported as indirect, and the form was filed by one reporting person.